2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee
Mark H. Drazner, Biykem Bozkurt, Leslie T. Cooper, Niti R. Aggarwal, Cristina Basso, Nicole M. Bhave, Alida L.P. Caforio, Vanessa M. Ferreira, Bettina Heidecker, Amy R. Kontorovich, Pilar Martín, Gregory A. Roth, Jennifer E. Van Eyk
{"title":"2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee","authors":"Mark H. Drazner, Biykem Bozkurt, Leslie T. Cooper, Niti R. Aggarwal, Cristina Basso, Nicole M. Bhave, Alida L.P. Caforio, Vanessa M. Ferreira, Bettina Heidecker, Amy R. Kontorovich, Pilar Martín, Gregory A. Roth, Jennifer E. Van Eyk","doi":"10.1016/j.jacc.2024.10.080","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Solution Set Oversight Committee</h2>Nicole M. Bhave, MD, FACC, <em>Chair</em>Niti R. Aggarwal, MD, FACCKatie Bates, ARNP, DNPJohn P. Erwin <span>iii</span>, MD, FACCMartha Gulati, MD, MS, FACCDharam J. Kumbhani, MD, SM, FACCGurusher S. Panjrath, MBBS, FACCBarbara Wiggins, PharmD, FACCMegan Coylewright, MD, MPH, FACC, <em>Ex Officio</em></section></section><section><section><h2>Table of Contents</h2><ul><li><span></span><span>Top 10 Key Takeaway Points<!-- --> <!-- -->3</span></li><li><span>1.</span><span>Introduction<!-- --> <!-- -->4</span></li><li><span>2.</span><span>Assumptions and Proposed Definitions<!-- --> <!-- -->4<ul><li><span>2.1.</span><span>General Clinical Assumptions<!-- --> <!-- -->4</span></li><li><span>2.2.</span><span>Definitions<!-- --> <!-- -->5</span></li></ul></span></li><li><span>3.</span><span>Pathway Summary Graphic<!-- --> <!-- -->5<ul><li><span></span><span>Figure 1. The Evaluation and Management of Clinically Suspected Myocarditis Described as a 5-Step Care Pathway<!-- --> <!-- -->6</span></li></ul></span></li><li><span>4.</span><span>Description, Rationale, and Implication of Pathway<!-- --> <!-- -->7<ul><li><span>4.1.</span><span>Diagnosis of Myocarditis<!-- --> <!-- -->7<ul><li><span>4.1.1.</span><span>Clinical Symptoms<!-- --> <!-- -->7<ul><li><span></span><span>Figure 2. Three Classic Presentations of Myocarditis<!-- --> <!-- -->8</span></li></ul></span></li></ul></span></li><li><span>4.2.</span><span>Diagnostic Testing<!-- --> <!-- -->7<ul><li><span>4.2.1.</span><span>Electrocardiogram<!-- --> <!-- -->7</span></li><li><span>4.2.2.</span><span>Echo and Strain Echocardiography<!-- --> <!-- -->7</span></li><li><span>4.2.3.</span><span>Circulating Cardiac Troponin<!-- --> <!-- -->7</span></li><li><span>4.2.4.</span><span></span></li></ul></span></li></ul></span></li></ul></section></section><section><section><h2>Top 10 Key Takeaway Points</h2><ul><li><span>1.</span><span>Clinicians need to be aware of the 3 classic presentations of myocarditis: chest pain, heart failure (HF)/shock, and/or symptoms related to arrhythmia (eg, presyncope or syncope). In a young person, the history of an antecedent viral infection, or other risk factors that define stage A at-risk for myocarditis, followed by any of these cardiovascular symptoms should raise the suspicion of this diagnosis.</span></li><li><span>2.</span><span>High-sensitivity cardiac troponin (hs-cTn) is a common diagnostic test in patients with</span></li></ul></section></section><section><section><section><h2>General Clinical Assumptions</h2><ul><li><span>1.</span><span>The principal focus of this ECDP is on adults with acute myocarditis. For information on myocarditis in the pediatric population, the reader is referred to the “2021 AHA Scientific Statement on Diagnosis and Management of Myocarditis in Children.”<sup>1</sup> This ECDP does not address conditions with chronic inflammatory infiltrates of the myocardium, as this was considered beyond the scope of the paper.</span></li><li><span>2.</span><span>The writing committee endorses the evidence-based approach to HF and cardiomyopathy diagnosis and</span></li></ul></section></section></section><section><section><h2>Pathway Summary Graphic</h2>Figure 1 provides a summary graphic outlining the 5-step process for evaluation and management of clinically suspected myocarditis. The initial step is to recognize that a patient's clinical presentation might be consistent with the diagnosis of myocarditis. Given the numerous ways that myocarditis can manifest (Figure 2 and Section 4.1.1), clinicians in a variety of healthcare settings need to be aware of this diagnosis. Examples include primary care physicians; rheumatologists; oncologists;</section></section><section><section><h2>Description, Rationale, and Implication of Pathway</h2>Based upon a comprehensive literature review and expert opinion, this ECDP aims to inform clinicians regarding the following: 1) the current diagnostic algorithm to follow in the setting of suspected myocarditis; 2) the pivotal role of advanced imaging and EMB in the confirmation of myocarditis; 3) when to refer patients to an advanced HF center and potential therapies for those with advanced myocarditis; 4) a new 4-stage classification of myocarditis, now including those “at-risk” for</section></section><section><section><h2>President and Staff</h2>Cathleen Biga, MSN, FACC, PresidentCathleen C. Gates, Chief Executive OfficerRichard J. Kovacs, MD, MACC, Chief Medical OfficerBrendan Mullen, Senior Executive Vice PresidentJoseph M. Allen, MA, Team Leader, Science & QualityAmy Dearborn, Team Leader, Decision ScienceAshleigh M. Covington, MA, Team Lead, Decision Science DeliveryAlan Shinkar, MPH, Project Manager, Decision Science DeliveryGrace D. Ronan, Senior Production and Operations Manager, Clinical Policy Publication</section></section>","PeriodicalId":17187,"journal":{"name":"Journal of the American College of Cardiology","volume":"19 1","pages":""},"PeriodicalIF":21.7000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacc.2024.10.080","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Section snippets
Solution Set Oversight Committee
Nicole M. Bhave, MD, FACC, ChairNiti R. Aggarwal, MD, FACCKatie Bates, ARNP, DNPJohn P. Erwin iii, MD, FACCMartha Gulati, MD, MS, FACCDharam J. Kumbhani, MD, SM, FACCGurusher S. Panjrath, MBBS, FACCBarbara Wiggins, PharmD, FACCMegan Coylewright, MD, MPH, FACC, Ex Officio
Table of Contents
Top 10 Key Takeaway Points 3
1.Introduction 4
2.Assumptions and Proposed Definitions 4
2.1.General Clinical Assumptions 4
2.2.Definitions 5
3.Pathway Summary Graphic 5
Figure 1. The Evaluation and Management of Clinically Suspected Myocarditis Described as a 5-Step Care Pathway 6
4.Description, Rationale, and Implication of Pathway 7
4.1.Diagnosis of Myocarditis 7
4.1.1.Clinical Symptoms 7
Figure 2. Three Classic Presentations of Myocarditis 8
4.2.Diagnostic Testing 7
4.2.1.Electrocardiogram 7
4.2.2.Echo and Strain Echocardiography 7
4.2.3.Circulating Cardiac Troponin 7
4.2.4.
Top 10 Key Takeaway Points
1.Clinicians need to be aware of the 3 classic presentations of myocarditis: chest pain, heart failure (HF)/shock, and/or symptoms related to arrhythmia (eg, presyncope or syncope). In a young person, the history of an antecedent viral infection, or other risk factors that define stage A at-risk for myocarditis, followed by any of these cardiovascular symptoms should raise the suspicion of this diagnosis.
2.High-sensitivity cardiac troponin (hs-cTn) is a common diagnostic test in patients with
General Clinical Assumptions
1.The principal focus of this ECDP is on adults with acute myocarditis. For information on myocarditis in the pediatric population, the reader is referred to the “2021 AHA Scientific Statement on Diagnosis and Management of Myocarditis in Children.”1 This ECDP does not address conditions with chronic inflammatory infiltrates of the myocardium, as this was considered beyond the scope of the paper.
2.The writing committee endorses the evidence-based approach to HF and cardiomyopathy diagnosis and
Pathway Summary Graphic
Figure 1 provides a summary graphic outlining the 5-step process for evaluation and management of clinically suspected myocarditis. The initial step is to recognize that a patient's clinical presentation might be consistent with the diagnosis of myocarditis. Given the numerous ways that myocarditis can manifest (Figure 2 and Section 4.1.1), clinicians in a variety of healthcare settings need to be aware of this diagnosis. Examples include primary care physicians; rheumatologists; oncologists;
Description, Rationale, and Implication of Pathway
Based upon a comprehensive literature review and expert opinion, this ECDP aims to inform clinicians regarding the following: 1) the current diagnostic algorithm to follow in the setting of suspected myocarditis; 2) the pivotal role of advanced imaging and EMB in the confirmation of myocarditis; 3) when to refer patients to an advanced HF center and potential therapies for those with advanced myocarditis; 4) a new 4-stage classification of myocarditis, now including those “at-risk” for
President and Staff
Cathleen Biga, MSN, FACC, PresidentCathleen C. Gates, Chief Executive OfficerRichard J. Kovacs, MD, MACC, Chief Medical OfficerBrendan Mullen, Senior Executive Vice PresidentJoseph M. Allen, MA, Team Leader, Science & QualityAmy Dearborn, Team Leader, Decision ScienceAshleigh M. Covington, MA, Team Lead, Decision Science DeliveryAlan Shinkar, MPH, Project Manager, Decision Science DeliveryGrace D. Ronan, Senior Production and Operations Manager, Clinical Policy Publication
期刊介绍:
The Journal of the American College of Cardiology (JACC) publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original clinical studies, experimental investigations with clear clinical relevance, state-of-the-art papers and viewpoints.
Content Profile:
-Original Investigations
-JACC State-of-the-Art Reviews
-JACC Review Topics of the Week
-Guidelines & Clinical Documents
-JACC Guideline Comparisons
-JACC Scientific Expert Panels
-Cardiovascular Medicine & Society
-Editorial Comments (accompanying every Original Investigation)
-Research Letters
-Fellows-in-Training/Early Career Professional Pages
-Editor’s Pages from the Editor-in-Chief or other invited thought leaders